DC in multiple myeloma immunotherapy

References

• Kumar A, Loughran T, Alsina M et al. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293— 304.
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123— 37.
   PubMedGoogle Scholar
• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245–87.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hart DNJ. Dendritic cells in tumor immunology and immunotherapy. Current Drug Targets 2004;5:17— 39.
   PubMed Web of Science ®Google Scholar
• Hart DN, Hill GR. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol 1999;77:451 — 9.
   PubMed Web of Science ®Google Scholar
• Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440— 52.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction ofmultiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435–42.
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of inter-leukin-6. Blood 2002;100:230— 7.
   PubMed Web of Science ®Google Scholar
• Chomarat P, Banchereau J, Davoust J et al. IL-6 switches the differentiation of monocytes from dendritic cells to macro-phages. Nat Immunol 2000;1:510–4.
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition ofthe differentiation of dendritic cells from CD34(± ) progenitors by rumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778— 91.
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Thomachot MC, Alberti L et al. IL-4 prevents the blockade of dendritic cell differentiation induced by rumor cells. Cancer Res 2001;61:3096— 104.
   PubMed Web of Science ®Google Scholar
• Xie J, Wang Y, Freeman ME, 3rd, et al. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003;101: 4005— 12.
   Google Scholar
• Brown RD, Pope B, Murray A et al. Dendritic cells from patientswith myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD4OLT stimulation because of inhibition by transforming growth factor-beta(1) and interleukin-10. Blood 2001;98:2992— 8.
   PubMed Web of Science ®Google Scholar
• Pfeiffer S, Gooding RP, Apperley JF et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br y Haematol 1997;98:973— 82.
   PubMed Web of Science ®Google Scholar
• Raje N, Gong J, Chauhan D et al. Bone marrow and peripheralblood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 1999;93:1487–95.
   PubMed Web of Science ®Google Scholar
• Vuckovic S, Kim M, Khalil D et al. Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003;101: 2314–7.
   PubMed Web of Science ®Google Scholar
• Fearnley DB, Whyte LF, Carnoutsos SA et al. Monitoring humanblood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999;93:728— 36.
   PubMed Web of Science ®Google Scholar
• Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administra-tion. Lupus 2003;12:222— 30.
   Google Scholar
• Woltman AM, Massacrier C, de Fijter JW et al. Corticosteroidsprevent generation of CD34 ± -derived dermal dendritic cells but do not inhibit Langerhans cell development. 7 Immunol 2002;168:6181–8.
   Google Scholar
• Yawalkar N, Karlen S, Egli F et al. Down-regulation of IL-12 bytopical corticosteroids in chronic atopic dermatitis. 7Allergy Clin Immunol 2000;106: 941— 7.
   Google Scholar
• Frassanito MA, Cusmai A, Dammacco E Deregulated cytokine network and defective Thl immune response in multiple myeloma. Clin Exp Immunol 2001;125:190— 7.
   PubMed Web of Science ®Google Scholar
• Valenzuela J, Schmidt C, Mescher M. The Roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. 7 Immunol 2002;169: 6842— 9.
   Google Scholar
• Camporeale A, Boni A, Iezzi G et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of rumor-specific T lymphocytes. Cancer Res 2003;63:3688–94.
   PubMed Web of Science ®Google Scholar
• Serra HM, Mant MJ, Ruether BA et al. Selective loss of CD4±CD45R± T cells in peripheral blood of multiple myeloma patients. 7 Clin Immunol 1988;8:259–65.
   PubMed Web of Science ®Google Scholar
• Lauritzsen GF, Hofgaard PO, Schenck K et al. Clonal deletion ofthymocytes as a rumor escape mechanism. Int 7 Cancer 1998;78:216— 22.
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Yuen E et al. The expression of T-cell related costimulatory molecules in multiple myeloma. Leuk Lymphoma 1998;31:379–84.
   PubMed Web of Science ®Google Scholar
• Raitakari M, Brown RD, Sze D et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br 7 Haematol 2000;110: 203–9.
   Google Scholar
• Brown RD, Yuen E, Nelson M et al. The prognostic significanceof T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997;11:1312–7.
   PubMed Web of Science ®Google Scholar
• Bomberger C, Singh-Jairam M, Rodey G et al. Lymphoid reconstitution after autologous PBSC transplantation with FAGS-sorted CD34± hematopoietic progenitors. Blood 1998;91:2588–600.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumormicroenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autolo-gous, rumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002;99:13009–13.
   Google Scholar
• Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUCI is expressed in hematological malignancies and is recognized by MUG 1-specific cytotoxic T-lymphocytes. Cancer Res 2001;61:6846–50.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002;100:961–5.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517–26.
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients withB-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52–7.
   PubMed Web of Science ®Google Scholar
• Yi Q, Desikan R, Barlogie B et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br 7 Haematol 2002;117:297–305.
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S et al.Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621–7.
   PubMed Web of Science ®Google Scholar
• Titzer S, Christensen 0, Manzke 0 et al. Vaccination of multiplemyeloma patients with idiotype-pulsed dendritic cells: immu-nological and clinical aspects. Br 7 Haematol 2000;108: 805–16.
   Google Scholar
• Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999;93:2411–9.
   PubMed Web of Science ®Google Scholar
• Wen YJ, Ling M, Bailey-Wood R et al. Idiotypic protein-pulsedadherent peripheral blood mononuclear cell- derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957–62.
   PubMed Web of Science ®Google Scholar
• Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int y Cancer 1999;83:215–22.
   PubMed Web of Science ®Google Scholar
• Butch AW, Kelly KA, Munshi NC. Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol 2001;29:85–92.
   Google Scholar
• Wen YJ, Barlogie B, Yi fit Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary rumor cells. Blood 2001;97:1750–5.
   PubMed Web of Science ®Google Scholar
• Ratta M, Curti A, Fogli M et al. Efficient presentation of rumor idiotype to autologous T cells by CD83(± ) dendritic cells derived from highly purified circulating CD14(± ) monocytes in multiple myeloma patients. Exp Hematol 2000;28:931–40.
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(± ) T cells. Blood 2000;96:2828–33.
   PubMed Web of Science ®Google Scholar
• Galea HR, Denizot Y, Cogne M. Light chain myeloma plasma cells induce a strong cell-mediated immune response mainly directed against the monoclonal light chain determinants in a murine experimental model. Cancer Immunol Immunother 2002;51:229–34.
   Google Scholar
• Sze DM-Y, Brown RD, Yang S et al. Prediction of high affinityclass I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma 2003;44:1557–68.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br y Haematol 2003;120:3–9.
   PubMed Web of Science ®Google Scholar
• Brossart P, Heinrich KS, Sruhler G et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC 1 rumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309–17.
   PubMed Web of Science ®Google Scholar
• Heukamp LC, van der Burg SH, Drijfhout JW et al. Identifica-tion of three non-VNTR MUC I -derived H LA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int 7 Cancer 2001;91: 385–92.
   Google Scholar
• Wykes M, MacDonald KP, Tran M et al. MUCI epithelial mucin(CD227) is expressed by activated dendritic cells. 7 Leukoc Biol 2002;72:692–701.
   PubMed Web of Science ®Google Scholar
• Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucingene expression in normal and neoplastic tissues. Cancer Res 1993;53:641–51.
   PubMed Web of Science ®Google Scholar
• Xu D, Zheng C, Bergenbrant S et al. Telomerase activity in plasma cell dyscrasias. Br 7 Cancer 2001;84:621–5.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Hahn WC, Schultze JL et al. The telomerasecatalytic subunit is a widely expressed rumor-associated antigen recognized by cytotoxic T lymphocytes. Immunio, 1999;10:673–9.
   PubMed Web of Science ®Google Scholar
• Scardino A, Gross DA, Alves P et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum rumor immunotherapy. 7 Immunol 2002;168: 5900–6.
   Google Scholar
• van Baren N, Chambost H, Ferrant A et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br Haematol 1998;102:1376–9.
   PubMed Web of Science ®Google Scholar
• Kessler JH, Beekman NJ, Bres-Vloemans SA et al. Efficient identification of novel HLA-A)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed rumor antigen PRAME by proteasome-mediated digestion analysis. 7 Exp Med 2001;193:73–88.
   PubMed Web of Science ®Google Scholar
• Matsushita M, Yamazaki R, Ikeda H et al. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies. Leuk Lymphoma 2003;44:439–44.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Mellerin MP, Labarriere N et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur 7 Immunol 2000;30:803— 9.
   PubMed Web of Science ®Google Scholar
• Lim SH, Wang Z, Chiriva-Internati M et al. Sperm protein 17 isa novel cancer-testis antigen in multiple myeloma. Blood 2001;97:1508— 10.
   PubMed Web of Science ®Google Scholar
• Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood 200198:2160–5.
   Google Scholar
• Grizzi F, Lim SH, Chiriva-Internati M, et al. Sperm protein 17 isnot expressed on normal leukocytes. Blood 2002;99:3479— 80 [author reply 3480— 1].
   Google Scholar
• Chiriva-Internati M, Wang Z, Xue Y et al. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur 7 Immunol 2001;31:2277— 83.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Wang Z, Salati E et al. Successful generation of sperm protein 17 (5p17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma. Scand Immunol 2002;56:429— 33.
   PubMed Web of Science ®Google Scholar
• van Baren N, Brasseur F', Godelaine D et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156— 64.
   Google Scholar
• Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hemato-poiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003;100:2742— 7.
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B et al. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. yExp Med 2002;195:125–33.
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt VL, Muller MR et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells trans-fected with tumor-derived RNA. Blood 2003;101:977–82.
   PubMed Web of Science ®Google Scholar
• Osman Y, Takahashi M, Zheng Z et al. Activation of autologousor HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Oncol Rep 1999;6:1057–63.
   PubMed Web of Science ®Google Scholar
• Wen YJ, Min R, Tricot G et al. Tumor lysate-specific cytotoxicT lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002;99:3280— 5.
   PubMed Web of Science ®Google Scholar
• Douek DC, Vescio RA, Betts MR et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000;355:1875–81.
   PubMed Web of Science ®Google Scholar
• Rutella S, Pierelli L, Sica S et al. Transplantation of autologousperipheral blood progenitor cells: impact of CD34-cell selection on immunological reconstitution. Leuk Lymphoma 2001;42:1207–20.
   PubMed Web of Science ®Google Scholar
• Motta MR, Castellani S, Rizzi S et al. Generation of dendriticcells from CD14± monocytes positively selected by immuno-magnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br y Haematol 2003;121:240— 50.
   PubMed Web of Science ®Google Scholar
• Choi D, Perrin M, Hoffmann S et al. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplanta-tion: CD34± cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 1998;4:2709— 16.
   PubMed Web of Science ®Google Scholar
• Barrow L, Brown RD, Murray A et al. CMRF44± dendritic cellsfrom peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination. Leuk Lymphoma 2003;44:2117–22.
   PubMed Web of Science ®Google Scholar
• Damiani D, Stocchi R, Masolini P et al. CD34± -selected versusunmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune recovery and on complications due to infection. Ann Oncol 2003;14:475— 80.
   PubMed Web of Science ®Google Scholar
• Cull G, Durrant L, Stainer C et al. Generation of anti-idiotypeimmune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br 7 Haematol 1999;107:648–55.
   PubMed Web of Science ®Google Scholar
• Rice A, Hart D. Technology evaluation: APC-80200, Dendreon. Curr Opin Mol Ther 2002;4:523–7.
   PubMedGoogle Scholar
• Lopez JA, Bioley G, Turtle CJ et al. Single step enrichment ofblood dendritic cells by positive immunoselection. 7 Immunol Methods 2003;274:47–61.
   PubMed Web of Science ®Google Scholar